Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Wiman

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|April 1, 1996
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levelsA Bröijersen, M Eriksson, B Wiman, et al.
European Journal of Clinical Investigation|April 1, 1997
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistanceM I Bokarewa, G Falk, K Bremme, et al.
Journal of Internal Medicine|October 9, 2002
The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or womenK Leander, B Wiman, J Hallqvist, et al.
Thrombosis and Haemostasis|June 28, 1990
Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysisP T Larsson, B Wiman, G Olsson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 11, 2000
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) studyB Wiman, T Andersson, J Hallqvist, et al.
The Journal of Laboratory and Clinical Medicine|February 1, 1985
The role of the fibrinolytic system in deep vein thrombosisB Wiman, B Ljungberg, J Chmielewska, et al.
Thrombosis and Haemostasis|September 1, 1994
Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusionE Moor, A Hamsten, M Blombäck, et al.
Thrombosis and Haemostasis|April 30, 1978
Molecular mechanisms of fibrinolysis in manA P Kaplan, F J Castellino, D Collen, et al.
Thrombosis and Haemostasis|June 12, 1999
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of AnticoagulationP Lindmarker, S Schulman, M Sten-Linder, et al.
The Journal of Biological Chemistry|May 25, 1993
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cellsS J Dawson, B Wiman, A Hamsten, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Arteriosclerosis, Thrombosis, and Vascular Biology|April 1, 1996
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levelsA Bröijersen, M Eriksson, B Wiman, et al.
European Journal of Clinical Investigation|April 1, 1997
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistanceM I Bokarewa, G Falk, K Bremme, et al.
Journal of Internal Medicine|October 9, 2002
The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or womenK Leander, B Wiman, J Hallqvist, et al.
Thrombosis and Haemostasis|June 28, 1990
Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysisP T Larsson, B Wiman, G Olsson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 11, 2000
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) studyB Wiman, T Andersson, J Hallqvist, et al.
The Journal of Laboratory and Clinical Medicine|February 1, 1985
The role of the fibrinolytic system in deep vein thrombosisB Wiman, B Ljungberg, J Chmielewska, et al.
Thrombosis and Haemostasis|September 1, 1994
Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusionE Moor, A Hamsten, M Blombäck, et al.
Thrombosis and Haemostasis|April 30, 1978
Molecular mechanisms of fibrinolysis in manA P Kaplan, F J Castellino, D Collen, et al.
Thrombosis and Haemostasis|June 12, 1999
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of AnticoagulationP Lindmarker, S Schulman, M Sten-Linder, et al.
The Journal of Biological Chemistry|May 25, 1993
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cellsS J Dawson, B Wiman, A Hamsten, et al.
Pageof 13